Objectives. Systemic rheumatoid vasculitis (SRV) is a rare but potentially serious systemic disease manifestation of rheumatoid arthritis (RA) characterized by the development of necrotizing vasculitis. The incidence of SRV appears to be decreasing possibly reflecting progress in RA treatment. The aims of this study were to review the clinical manifestations of SRV in a stable well-defined population during 200110 and to compare with our previous cohort (19882000) and also a cohort from 1975 to 1981.
Introduction
Background Systemic rheumatoid vasculitis (SRV) was first described in the 19th century in a patient with involvement of the vasa nervorum. The classical clinical features of peripheral gangrene and mononeuritis multiplex were described in the 1940s and 1950s by Bywaters et al. [1, 2] . SRV typically occurs in male patients with long-standing seropositive erosive nodular RA and is associated with a severe disease course and extra-articular manifestations (EAMs), including nodules and pulmonary fibrosis [3, 4] . Any size of blood vessel may be involved, from aorta to capillaries, with widespread organ involvement. The prognosis of SRV in general is thought to be poor. However, vasculitis may be confined to the nailfolds [i.e. isolated nailfold vasculitis (NFV)], and this has a better prognosis and does not usually herald the onset of systemic disease [5, 6] .
During the 1990s and 2000s the treatment paradigm for RA significantly changed, with a treat-to-target approach and focus on early and aggressive control of inflammation [79] . In the late 1980s and 1990s MTX began to be used more widely and earlier in the treatment course of RA, while in the 2000s biologic therapies were introduced. Several studies have suggested that there has been a change in the severity of RA, with a decline in the occurrence of extraarticular disease and vasculitis during this time [10, 11] .
The Norfolk Vasculitis Register (NORVASC) was established in 1988 and prospectively identifies all patients with systemic vasculitis who attend the Norfolk and Norwich University Hospital (NNUH). This is the central referral hospital for a stable, ethnically homogeneous population of 500 000. The NORVASC register thus provides the opportunity to study long-term changes in the incidence and prevalence of SRV from a geographically well-defined population. Norfolk is ideal for epidemiological studies and provides a representative denominator population for many RA-related studies and large prospective registries [Norfolk Arthritis Register (NOAR), NORVASC] [12] . Herein we present data from the longest prospective epidemiological study of SRV, looking for evidence of changes in occurrence, clinical features and outcome.
Aim of the study
The aim of this study was to investigate the incidence, clinical manifestations and outcome of SRV in a stable, well-defined population in the biologic era (200110) and to compare the clinical features of SRV with a previous cohort of patients (19882000) drawn from the same population in Norfolk [6] as well as with a cohort of patients from the 1970s (197581) based in Bath [3].
Methods

Case capture
Using NORVASC, all patients with a diagnosis of SRV from 1 January 1988 until 31 December 2010 were identified. In addition, all patients attending the NNUH as daycase admissions or hospitalized with a clinical diagnosis of systemic vasculitis were identified using the hospital discharge diagnostic index using the International Classification of Diseases (9th and 10th revisions) codes. Furthermore, the databases and records of all patients in the rheumatology day unit receiving treatment with i.v. pulse cyclophosphamide (CYC) or rituximab were also reviewed. Finally, all clinicians in the Rheumatology Department were asked to refer any patients with SRV not already registered with NORVASC. Patients from the denominator population (defined below) were identified. A retrospective review of the complete case notes was performed to establish the diagnosis of SRV and confirmed by an independent physician not directly involved in the care of patients (R.A.W.).
SRV was defined according to the Scott and Bacon criteria (1984) [13] requiring the presence of one or more of the following in a patient with RA: (i) mononeuritis multiplex or peripheral neuropathy, (ii) peripheral gangrene, (iii) biopsy evidence of acute necrotizing arteritis plus systemic illness (e.g. fever and weight loss), (iv) deep cutaneous ulcers or extra-articular disease (e.g. pleurisy, pericarditis and scleritis) if associated with typical digital infarcts or biopsy evidence of vasculitis. Other causes of such lesions, such as atherosclerosis and diabetes mellitus, were excluded. Nailfold lesions were considered to be isolated if they occurred in the absence of any of the above features of SRV. RA was diagnosed using the ACR 1987 criteria [14] .
Patients with other types of systemic vasculitis, such as granulomatosis with polyangiitis (Wegener's) (GPA), polyarteritis nodosa, microscopic polyangiitis (MPA), eosinophilic GPA (ChurgStrauss), IgA vasculitis (HenochSchö nlein), hypersensitivity vasculitis and vasculitis secondary to other connective tissue disease were excluded. Patients living outside the geographical area of the (former) Norwich Health Authority were also excluded.
Denominator population
The denominator population comprised patients registered with general practitioners or primary care physicians in the (former) Norwich Health Authority. Patients must be registered with a general practitioner in order to access the UK National Health Service; consequently virtually the whole population is registered.
The denominator adult population (age >15 years) has increased during the study. The population in 1992 was 413 500 (females 135 000), in 1997 it was 429 000 (females 222 000) and in 2001 it was 444 500 (females 230 500). We estimated the 2008 population (midpoint of the last 5-year period, 200510), assuming a linear rate of growth of 3.75%, using population growth estimates for the local population obtained from the UK 2001 census [15] . In 2008 the estimated adult population age >15 years was 459 000 (females 238 000). Age and sex distribution data were available to enable the calculation of age-and sex-specific incidence rates. The population is 97% white Caucasian, which is greater than the average for England (91%). The proportion of the population age >65 years is 20.9%, which is greater than the average for England of 15.9%.
Statistical analysis
Continuous variables are expressed as median and 25th and 75th centiles. Categorical variables are presented as percentages and frequencies. Age-and sex-specific incidence rates were calculated for each time point using the appropriate corresponding population as the denominator. The 95% CIs were calculated using the Poisson distribution for the observed number of cases. The incidence was also calculated using 3-year centred moving averages. Survival was calculated using the KaplanMeier method with log rank test for cohort comparison. To compare patients with a diagnosis of SRV in the extended Norfolk study, the patients were divided into two cohorts: 19882000 (pre-biologic era) and 200110 (biologic era). In addition, mortality was compared with a previously published cohort of NFV patients drawn from the same population [5] . Clinical features were compared with the previously described 19882000 Norwich cohort [6] and the 197581 Bath cohort [3] using a chi-square test. Cox regression was used to model the effects of age and cohort on survival. A two-tailed P-value 40.05 was considered statistically significant. Data were analysed using SPSS version 19 (IBM Inc.). The Norfolk Research Ethics Committee provided ethics approval for the study. As this was a registry study using anonymized routinely collected data, we were not required to obtain individual written consent.
Results
Demography
Thirty-four patients with a new diagnosis of SRV were identified during the period from 1 January 2001 to 31 December 2010 and their medical records were reviewed. Of these patients, 18 (10 male) from the denominator population fulfilled the inclusion criteria and were included in the study. All patients were adults. The remaining patients were not resident in the denominator population at the time of diagnosis (1 case), had an original diagnosis before 2001 (3 cases), did not fulfil the clinical criteria (11 cases) or had an alternative diagnosis (3 cases). All patients included in the study were identified from the prospective register and there were no additional cases from the alternative sources, such as coding or day unit records. Details of the patients' characteristics, cumulative followup and disease duration are reported in Table 1 .
Comorbidities, including cardiovascular disease, diabetes or other connective tissue conditions, were recorded for patients in the 200110 cohort. Fifteen patients (83%) had atherosclerosis, two patients (11%) had documented ischaemic heart disease with previous myocardial infarction and four patients (22%) had peripheral vascular disease. Two patients (11%) had documented atrial fibrillation and congestive heart failure and three (17%) had previous cerebrovascular events. There were four patients with type 2 diabetes in this cohort, two of whom were on insulin treatment. There were two patients with secondary SS.
Smoking status was reviewed at the time of SRV diagnosis and five (28%) patients were current smokers, seven (38%) were ex-smokers and five (27%) were nonsmokers. Smoking status was unknown for one patient, but overall 39% of patients were considered heavy smokers (>20 pack-years). We did not have comparable data for the 19882000 cohort.
Immunology
All patients were seropositive for RF, however, anti-CCP status was not available for any of the patients because the test was not routinely available at the time of diagnosis. Five patients were pANCA positive by indirect immunofluorescence assay, with negative ELISA for MPO. One patient was pANCA positive with PR3 antibodies but negative for MPO antibodies. There were no cANCA-positive patients. All patients were negative for ANA, but one patient had positive anti-mitochondrial antibodies.
Incidence
The average annual incidence for the Norwich cohorts is reported in Table 1 and illustrated in Fig. 1 as a 3-year rolling incidence. There was no significant difference in incidence between men and women. The 200110 incidence is significantly lower than that observed in the 19882000 cohort.
Clinical features
The clinical features of SRV patients in the 200110 cohort were compared with the previous cohort from 1988 to 2000 [6] and a cohort from the 1970s [3], as shown in Table 2 . The data about erosive or nodular disease and seropositivity is cumulative, however, the other features represent symptoms at the time or within 3 months of SRV diagnosis. In the 200110 cohort, in six of the eight patients with reported deep cutaneous ulcers the diagnosis of SRV was made solely based on the presence of Scott and Bacon criteria. Four of these patients had histological confirmation of vasculitis and in the other cases diagnosis was made in combination with the presence of EAMs or digital infarcts. In one case the ulcer aetiology was mixed arterial and due to biomechanical reasons, but that patient also fulfilled another criterion for SRV, therefore the diagnosis was not based on the presence of this ulcer alone. With respect to neurological features, confirmation was obtained with nerve conduction studies (eight patients) and in two cases with sural nerve biopsy for patients with neuropathy. There were no obvious alternative clinical causes for peripheral neuropathy documented. There were four patients in whom the diagnosis of SRV was based solely on neurological criteria. In all four cases there was neurophysiological confirmation of the pathology and in one case there was histopathological evidence from a sural nerve biopsy. Renal involvement was documented as the presence of haematuria/proteinuria or increased creatinine not explained by another disease within 3 months of SRV diagnosis. No patients underwent a renal biopsy. There were four patients with echocardiographic evidence of pericarditis or the presence of a pericardial effusion at the time of diagnosis, but no myocardial infarctions were reported within 3 months of the diagnosis, although there were patients with a history of a previous MI preceding the onset of SRV.
Cohort comparison
There were no significant differences noted in the overall broad categories, except for systemic symptoms and cutaneous manifestations such as infarcts and nodules, which were less common in the 200110 cohort (P < 0.05).
Treatment
Prior to SRV diagnosis, patients in the 200110 cohort had used a median of two DMARDs (average 2.6, range 06). Details of the DMARDs patients had been treated with prior to the diagnosis of SRV (cumulative) are shown on Table 3 . Only two patients had previous therapy with biologic drugs and none had received rituximab. All patients had received glucocorticoids at some point during the Values are n or n (%). Cohort comparison reaching statistical significance (P < 0.05): course of their RA treatment. Reported reasons for failing a specific DMARD included toxicity, lack of efficacy and compliance issues. Most patients had treatment adjustments (stopping/restarting the same DMARD or switching DMARDs) prior to SRV diagnosis. Accurate correlation with their disease (DAS score) was not possible due to poor documentation. At the time of SRV diagnosis 11 patients (61%) were on steroids, 6 of which were in combination with DMARDs, leaving 5 patients on steroids alone mainly due to intolerance or compliance reasons.
Treatment for SRV
All but one patient in the 200110 cohort received i.v. CYC (1015 mg/kg/pulse) and methylprednisolone for treatment of SRV (94%). CYC treatment followed standard protocols used for ANCA vasculitis [16] . The patients received a median of 6 (range 314) cycles. All patients received pulsed methylprednisolone in combination with the initial CYC pulse and thereafter were on oral glucocorticoids. Patients in the 19882000 cohort were mainly treated with glucocorticoids either orally or intravenously together with CYC, however, this was not protocolized [13] .
Mortality
Of the 18 patients in the 200110 cohort, 10 were deceased at the time of the study and a cause of death was documented for 8 of them with a post-mortem performed in two cases. In four patients (40% of the deceased) the cause of death related to cardiovascular disease and in four cases death was due to septicaemia (although in one of those cases the primary cause documented was metastatic carcinomatosis). The cumulative 1-year mortality for the 200110 cohort was 12% and the 5-year mortality was 60%. There was no difference in mortality between this and the 19882000 cohort, in whom the 1-and 5-year mortality was 14% and 51% (P = 0.134) (Fig. 2a) . Following adjustment for age at Some patients were on combination therapy. Cumulative column reports the number of patients ever on that DMARD prior to SRV diagnosis.
www.rheumatology.oxfordjournals.org diagnosis of SRV, there was still no significant difference in mortality (P = 0.211). Mortality therefore remains high. There was no difference in mortality between men and women overall (P = 0.523). As reported previously, NFV has a much better prognosis than SRV (Fig. 2b) . Table 4 shows the survival for 1, 2, 5 and 10 years for the SRV and NFV cohorts.
Discussion
This study extends our previous report [6] on the incidence of SRV and provides prospectively collected data over a 22-year period based on a stable cohort of patients in the UK. It is also the first study that allows comparison of clinical features between UK-based cohorts spanning >4 decades. Our results show that there has been a significant decrease in the incidence of SRV in the last decade. This finding is compatible with other recent studies both from Europe and the USA. A recent population-based US study looking at the incidence of extra-articular RA reported a reduction in the 10-year cumulative incidence of SRV from 3.6% in 198594 to 0.6% in 19952007 [17] . A reduction in the prevalence of SRV has also been reported in a serial cross-sectional study looking at both hospitalized and ambulatory patients from the US veteran population during 19852006, comprising a similar duration of cohort observation with our study of 22 years [18] . There was also a decline in hospitalizations in California of SRV patients between 1980 and 2001 [19] .
This decline in the incidence of SRV may be attributable to a change in DMARD usage, and more specifically the increased use of MTX as a first-line agent. Data from the General Practice Research Database, a national database containing records of >7 million patients across the UK, looking at changing trends in the prescribing of DMARDs for RA, has shown that in the east of England, the proportion of patients receiving MTX at 12 months has increased from 13% in 199599 to 37% in 200610 [9] . Furthermore, the time to first DMARD decreased from 9 to 6 months in a NOAR study of inflammatory arthritis diagnosed during the 1990s and 2000s [20] . In the east of England, overall use of DMARDs 12 months after the diagnosis of RA was 56% [9] .
It is possible that the reduction in the incidence of SRV in our population reflects a change in the population or failure to capture cases. We analysed the occurrence of ANCA vasculitis during the same period and the incidence of GPA and MPA remained stable [21] . An alternative explanation is that the severity of RA has decreased independently of the effects of changing treatment and this might have started before the introduction of modern immunosuppressive therapy [22] . Furthermore, some reports based on the NOAR, which is set in the same catchment area, suggest that the prevalence of RA in the UK seems to be declining since the 1950s [23] . However, the rate of reduction in RA incidence is far less compared with the rate of decline in the incidence of SRV.
Smoking is considered a significant risk factor for the development of RA [24] , but also an independent predictor of SRV and other types of severe EAM [11, 25] . In our cohort, 28% of our patients were current smokers at the time of SRV diagnosis. Data from the NOAR database indicates that in 199094, 28.5% of patients with newonset inflammatory arthritis were smokers and 26% in 200004 [20] . Data from the office for national statistics in 2010 on the prevalence of adult cigarette smoking in the east of England suggest a 20% rate for males and 17% for females [26] . There are no available data for ever use of tobacco for our denominator population. It is therefore not possible to draw any conclusions from our data regarding the association of smoking and the development of SRV.
Other commonly reported risk factors associated with the occurrence of severe EAM, and more specifically SRV, include RF positivity, erosive/destructive disease and long duration of RA disease [17] . In our study we compared clinical features of SRV cohorts spanning three different decades (1970, 1990 and 2000) . In all cohorts, patients were predominately seropositive for RF, with documented erosive disease in 6883% of cases in the Norwich cohorts. A significant difference was noted mainly in the cutaneous disease manifestations, more so between the 1970 cohort and the 2000 cohort. Leg ulcers are now much less frequent; whether this is due to the changing use of glucocorticoids we cannot determine from our data, as we do not have data on cumulative steroid use. Possible explanations for this difference may be the fact that cutaneous features are poorly documented on medical records and may not be adequately captured. The same is true for systemic disease manifestations such as documented weight loss or malaise. Although not reaching statistical significance, pulmonary manifestations were somewhat more common in the recent cohort, which is in line with previous studies that reported a decline of other EAMs, but not lung involvement [11, 17] . Overall there were no significant changes in the clinical profile of SRV, consistent with other studies that do not show a change in the pattern of EAMs, despite the reduction in incidence. However, the absence of significant differences of incidence in symptomatology between cohorts does not confirm that the severity has not declined, as a type 2 error is highly probable. In addition, given the relatively small number of patients included, one must be circumspect when making associations between risk factors and clinical presentations. The morbidity and mortality of SRV remains significant and has not improved between the two cohorts, despite the use of a CYC regimen similar to that used for ANCA associated vasculitis (AAV). Indeed, this has not improved since the 1970s, when mortality of 24% at 2 years was reported [3] . We have confirmed the previous observation that NFV carries a much better prognosis than SRV [6] . A NOAR study looking at the 5-and 10-year mortality of patients with recent-onset inflammatory polyarthritis in the same catchment area suggested that extra-articular/ vascular inflammation identifies patients at particularly high cardiovascular disease risk, which is in accordance with our cardiovascular mortality findings [27] . There has been a shift in the SRV case age, with a more mature age of cases in the recent cohort. This was taken into consideration when comparing the survival trends, which suggest there is no improvement in survival even when these were adjusted for age.
There were some inherent weaknesses and limitations in our study. Although the cases were prospectively registered, clinical information was retrieved retrospectively from medical notes, with an inevitable difficulty in recording all required data. We feel that the capture strategy for SRV patients was robust, as we used different methods to identify patients from alternative sources but these methods did not reveal any additional cases. Furthermore, as NNUH is the main referral centre for complex RA and the central referral hospital for the catchment area, it is likely that all patients with SRV would be referred there for specialist care.
Despite the relatively small number of patients included in this study (n = 18), this report reflects the rarity of the disease and is consistent with previous studies both in the UK and internationally. As the same database and methodology was utilized to review and compare the two Norwich cohorts, this allowed for more accurate comparison of epidemiological data and clinical features. However, we acknowledge there may have been limitations relating to different documentation patterns by era and location when comparing the two Norwich cohorts with the Bath cohort.
In conclusion, the incidence of SRV in the era of modern immunosuppressive therapy, i.e. the biologic era, is low compared with the 1990s. However, clinical features are similar and mortality remains high. Modern therapy for RA has possibly been associated with a decrease in the incidence of SRV but has not had any significant influence on clinical manifestations or outcome.
Rheumatology key messages
. The incidence of SRV in England has declined significantly in the past 40 years. . The present clinical manifestations of SRV remain similar to those of the 1990s. . Despite modern immunosuppressive therapy, the prognosis of SRV remains poor.
